Skip to main content
Autobound logo

What Incyte's latest 10-Q says: 9 signals

Incyte filed its latest 10-Q with the SEC on Jul 28, 2026. It discusses AI investment, capex increase and CFO change.

Public (INCY)Pharmaceutical Manufacturing5,001 to 10,000 employeesincyte.comLinkedIn

Filed
Jul 28, 2026
Filings
2
Signals
20

10-Q · latest 10

What Incyte's 10-Q filings say

  1. 10-Q

    Filed · 9 signals

    SEC EDGAR

  2. 10-Q

    Filed · 11 signals

    SEC EDGAR

Showing 10 of 20 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Incyte earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Raised full-year revenue guidance after strong quarterThe company increased its full-year 2025 net product revenue guidance to over $4.2 billion, reflecting strong sales momentum and financial health. This indicates ample budget for strategic investments and new vendor solutions.
Preparing for three major new product launches in 2026Three significant products are launching next year, which will require substantial investment in commercial infrastructure, including sales force preparations, payer engagements, and medical education initiatives.
CEO launching company-wide cost review to improve margins and reallocate capitalLeadership is conducting a review of the entire business focused on prioritization and data-driven trade-offs to manage costs. This creates opportunities for solutions that improve ROI, offer cost savings, or provide better data for financial decision-making.
Creating 'ring-fenced' budgets for non-negotiable growth programsLeadership is explicitly protecting budgets for strategic growth drivers, including new product launches and key R&D projects, designating them as 'nonnegotiable, fully funded programs' for the 2026 budget and beyond.
CEO implementing strategic review to reallocate capital to high-value projectsA company-wide review is underway to shift spending from low-value areas to high-return opportunities. This creates an opening for vendors whose solutions can demonstrate clear ROI and alignment with core growth drivers.
Announced strong 20% Y/Y revenue growthTotal revenues grew 20% to $1.37 billion, driven by strong performance across key products. This rapid growth provides significant operating leverage and capital to fund new initiatives.

Signal API · MCP

Track Incyte with the Signal API

One POST /v1/companies/enrich call with incyte.com returns Incyte 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","signal_types":["sec-10q"],"limit":20}'

Same industry

10-Q at related companies

Questions about Incyte 10-Q

When did Incyte file its latest 10-Q?
Incyte filed its latest 10-Q on Jul 28, 2026. The one before it was filed on Apr 28, 2026.
What did Incyte disclose in its latest 10-Q?
From the filing dated Jul 28, 2026: Incyte appoints Suketu Upadhyay as new Executive Vice President and Chief Financial Officer.
What did Incyte say on its recent earnings calls?
Q3 FY2025: Raised full-year revenue guidance after strong quarter (dated Oct 28, 2025).
Where can I read Incyte's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →